

## Complete Summary

---

### GUIDELINE TITLE

Premature rupture of membranes.

### BIBLIOGRAPHIC SOURCE(S)

American College of Obstetricians and Gynecologists (ACOG). Premature rupture of membranes. Washington (DC): American College of Obstetricians and Gynecologists (ACOG); 1998 Jun. 10 p. (ACOG practice bulletin; no. 1). [70 references]

### GUIDELINE STATUS

This is the current release of the guideline.

According to the guideline developer, this guideline is still considered to be current as of December 2004, based on a review of literature published that is performed every 18-24 months following the original guideline publication.

## COMPLETE SUMMARY CONTENT

SCOPE  
 METHODOLOGY - including Rating Scheme and Cost Analysis  
 RECOMMENDATIONS  
 EVIDENCE SUPPORTING THE RECOMMENDATIONS  
 BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS  
 QUALIFYING STATEMENTS  
 IMPLEMENTATION OF THE GUIDELINE  
 INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT  
 CATEGORIES  
 IDENTIFYING INFORMATION AND AVAILABILITY  
 DISCLAIMER

## SCOPE

### DISEASE/CONDITION(S)

Premature rupture of membranes in pregnancy

### GUIDELINE CATEGORY

Diagnosis  
 Evaluation  
 Management  
 Prevention

## CLINICAL SPECIALTY

Obstetrics and Gynecology  
Pediatrics

## INTENDED USERS

Physicians

## GUIDELINE OBJECTIVE(S)

- To aid practitioners in making decisions about appropriate obstetric and gynecologic care
- To review the current understanding of premature rupture of membranes (PROM) and to provide management guidelines that have been validated by appropriately conducted outcome-based research

## TARGET POPULATION

Pregnant women with suspected premature rupture of membranes

## INTERVENTIONS AND PRACTICES CONSIDERED

### Diagnosis/Evaluation

1. History and physical examination including sterile speculum examination and visualization of amniotic fluid in the posterior vaginal fornix or clear fluid passing from the cervical canal
2. pH of the vaginal sidewalls or fluid pool
3. Ultrasound examination
4. Assessment of fetal presentation and gestational age
5. Fetal heart rate monitoring to assess fetal status
6. Assessment of group B streptococcal status and the need for intrapartum prophylaxis
7. Assessment of fetal pulmonary maturity

### Management

1. Induction of labor (32 to 36 weeks of gestation)
2. Expectant management (stable condition and less than 30 to 32 weeks of gestation) including modified bed rest, periodic assessment for maternal infection, fetal surveillance, counseling women presenting before presumed fetal viability
3. Tocolysis
4. Prophylactic antibiotics (intravenous ampicillin and erythromycin followed by oral amoxicillin and erythromycin OR intravenous ampicillin followed by oral amoxicillin OR intravenous ampicillin/sulbactam followed by oral amoxicillin/clavulanate)
5. Antenatal corticosteroids

## MAJOR OUTCOMES CONSIDERED

- Risk factors associated with premature rupture of membranes (PROM)
- Rate of maternal and fetal complications associated with PROM
- Infant survival rates in pregnancies complicated by PROM

## METHODOLOGY

### METHODS USED TO COLLECT/SELECT EVIDENCE

Hand-searches of Published Literature (Primary Sources)  
 Hand-searches of Published Literature (Secondary Sources)  
 Searches of Electronic Databases

### DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

The MEDLINE database, the Cochrane Library, and American College of Obstetricians and Gynecologists' (ACOG's) own internal resources and documents were used to conduct a literature search to locate relevant articles published between 1980 and August 1997. The search was restricted to articles published in the English language. Priority was given to the articles reporting results of original research although review articles and commentaries also were consulted. Abstracts of research presented at symposiums and scientific conferences were not considered adequate for inclusion in this document.

Guidelines published by organizations or institutions such as the National Institutes of Health and ACOG were reviewed, and additional studies were located by reviewing bibliographies of identified articles.

### NUMBER OF SOURCE DOCUMENTS

Not stated

### METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Weighting According to a Rating Scheme (Scheme Given)

### RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Studies were reviewed and evaluated for quality according to the method outlined by the U.S. Preventive Services Task Force.

I Evidence obtained from at least one properly designed randomized controlled trial

II-1 Evidence obtained from well-designed controlled trials without randomization

II-2 Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group

II-3 Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments also could be regarded as this type of evidence.

III Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees

## METHODS USED TO ANALYZE THE EVIDENCE

Review of Published Meta-Analyses  
Systematic Review

## DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Not stated

## METHODS USED TO FORMULATE THE RECOMMENDATIONS

Expert Consensus

## DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS

Analysis of available evidence was given priority in formulating recommendations. When reliable research was not available, expert opinions from obstetrician-gynecologists were used. See also the "Rating Scheme for the Strength of Recommendations" field regarding Grade C recommendations.

## RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Based on the highest level of evidence found in the data, the recommendations are provided and graded according to the following categories:

- A. The recommendation is based on good and consistent scientific evidence.
- B. The recommendation is based on limited or inconsistent scientific evidence.
- C. The recommendation is based primarily on consensus and expert opinion.

## COST ANALYSIS

A formal cost analysis was not performed and published cost analyses were not reviewed.

## METHOD OF GUIDELINE VALIDATION

Internal Peer Review

## DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

Practice Bulletins are validated by two internal clinical review panels composed of practicing obstetrician-gynecologists generalists and sub-specialists. The final

guidelines are also reviewed and approved by the American College of Obstetricians and Gynecologists (ACOG) Executive Board.

## RECOMMENDATIONS

### MAJOR RECOMMENDATIONS

The grades of evidence (I-III) and levels of recommendations (A-C) are defined at the end of "Major Recommendations" field.

The following recommendations are based on good and consistent scientific evidence (Level A):

- With term premature rupture of membranes (PROM), labor may be induced at the time of presentation or patients may be observed for up to 24 to 72 hours for the onset of spontaneous labor.
- Antibiotics prolong the latency period and improve perinatal outcome in patients with preterm PROM and should be administered according to one of several published protocols if expectant management is to be pursued prior to 35 weeks of gestation.
- Antenatal corticosteroids should be administered to gravidas with PROM before 32 weeks of gestation to reduce the risks of respiratory distress syndrome, neonatal intraventricular hemorrhage, necrotizing enterocolitis, and neonatal death.
- Digital cervical examination should not be performed in patients with PROM who are not in labor and in whom immediate induction of labor is not planned.
- Patients with PROM prior to 30 to 32 weeks of gestation should be managed conservatively if no maternal or fetal contraindications exist.

The following recommendations are based primarily on consensus and expert opinion (Level C):

- Tocolysis may be utilized in patients with preterm PROM to permit administration of antenatal corticosteroids and antibiotics.
- Antenatal corticosteroids may be administered to gravidas with PROM up to 34 weeks of gestation.

### Definitions:

#### Grades of Evidence

I Evidence obtained from at least one properly designed randomized controlled trial

II-1 Evidence obtained from well-designed controlled trials without randomization

II-2 Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group

II-3 Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments could also be regarded as this type of evidence.

III Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees

#### Levels of Recommendations

- A. The recommendation is based on good and consistent scientific evidence.
- B. The recommendation is based on limited or inconsistent scientific evidence.
- C. The recommendation is based primarily on consensus and expert opinion.

#### CLINICAL ALGORITHM(S)

None provided

### EVIDENCE SUPPORTING THE RECOMMENDATIONS

#### TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is identified and graded for each recommendation (see "Major Recommendations").

### BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

#### POTENTIAL BENEFITS

##### Overall Benefits

Improved understanding and management of premature rupture of membranes (PROM)

##### Specific Benefits

- Corticosteroid use in women with PROM prior to 30 to 32 weeks of gestation reduces respiratory distress syndrome. The benefit of antenatal corticosteroids may outweigh the risk in patients between 24 and 32 weeks of gestation.
- Antibiotic therapy in patients with preterm PROM have been shown to prolong pregnancy and reduce chorioamnionitis, postpartum endometritis, pneumonia, intraventricular hemorrhage, and perinatal morbidity including neonatal sepsis, respiratory distress syndrome, and necrotizing enterocolitis.

#### POTENTIAL HARMS

Because of the possible adverse fetal effects and possible effects on maternal immune status of repeated weekly courses of antenatal corticosteroids, the repeated doses should only be given on an as needed basis.

## QUALIFYING STATEMENTS

### QUALIFYING STATEMENTS

These guidelines should not be construed as dictating an exclusive course of treatment or procedure. Variations in practice may be warranted based on the needs of the individual patient, resources, and limitations unique to the institution or type of practice.

## IMPLEMENTATION OF THE GUIDELINE

### DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

## INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

### IOM CARE NEED

Getting Better  
Staying Healthy

### IOM DOMAIN

Effectiveness  
Safety

## IDENTIFYING INFORMATION AND AVAILABILITY

### BIBLIOGRAPHIC SOURCE(S)

American College of Obstetricians and Gynecologists (ACOG). Premature rupture of membranes. Washington (DC): American College of Obstetricians and Gynecologists (ACOG); 1998 Jun. 10 p. (ACOG practice bulletin; no. 1). [70 references]

### ADAPTATION

Not applicable: The guideline was not adapted from another source.

### DATE RELEASED

1998 Jun (reviewed 2004)

### GUIDELINE DEVELOPER(S)

American College of Obstetricians and Gynecologists - Medical Specialty Society

## SOURCE(S) OF FUNDING

American College of Obstetricians and Gynecologists (ACOG)

## GUIDELINE COMMITTEE

American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics

## COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Not stated

## FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

## GUIDELINE STATUS

This is the current release of the guideline.

According to the guideline developer, this guideline is still considered to be current as of December 2004, based on a review of literature published that is performed every 18-24 months following the original guideline publication.

## GUIDELINE AVAILABILITY

Electronic copies: Not available at this time.

Print copies: Available for purchase from the American College of Obstetricians and Gynecologists (ACOG) Distribution Center, PO Box 4500, Kearneysville, WV 25430-4500; telephone, 800-762-2264, ext. 192; e-mail: [sales@acog.org](mailto:sales@acog.org). The ACOG Bookstore is available online at the [ACOG Web site](#).

## AVAILABILITY OF COMPANION DOCUMENTS

None available

## PATIENT RESOURCES

None available

## NGC STATUS

This NGC summary was completed by ECRI on January 14, 2005.

## COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.



## DISCLAIMER

### NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2006 National Guideline Clearinghouse

Date Modified: 9/25/2006

